Prelude Therapeutics raises $60M in Series B round for solid tumor blood cancer drug

Prelude Therapeutics raises $60M in Series B round for solid tumor, blood cancer drug

The company is developing a PRMT5 inhibitor, currently in a Phase I study for lymphomas, myeloid malignancies and solid tumors.

More From BioPortfolio on "Prelude Therapeutics raises $60M in Series B round for solid tumor, blood cancer drug"